Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

Trials

Volumn 12, Issue , 2011, Pages

  Davis, Jeremy L ^a   Pandalai, Prakash ^a   Ripley, R Taylor ^a   Langan, Russell C ^a   Steinberg, Seth M ^a   Walker, Melissa ^a   Toomey, Mary A ^a   Levy, Elliot ^a   Avital, Itzhak ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTIFICIAL EMBOLISM; CANCER INVASION; CLINICAL TRIAL; METHODOLOGY; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; REGIONAL PERFUSION; TREATMENT OUTCOME; UNITED STATES; VASCULARIZATION;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DEOXYCYTIDINE; EMBOLIZATION, THERAPEUTIC; HUMANS; MARYLAND; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PANCREATECTOMY; PANCREATIC NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 79956029770     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-129     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA: a cancer journal for clinicians 2010, 60:277-300. 2010.
2. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189:1-7. 10.1016/S1072-7515(99)00075-7, 10401733.
3. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007, 297:267-277. 10.1001/jama.297.3.267, 17227978.
4. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006, 3:CD002093.
5. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984, 2:498-504.
6. Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958, 148:616-632. 10.1097/00000658-195810000-00009, 1450870, 13583933.
7. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM, Alexander HR, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006, 24:4196-4201. 10.1200/JCO.2005.05.5152, 16943537.
8. Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, Bartlett DL. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999, 6:582-590. 10.1007/s10434-999-0582-6, 10493628.
9. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:1001-1007.
10. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest 2005, 23:145-154.
11. Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?. J Urol 183:56-61.
12. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9:491-498.
13. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21:3402-3408. 10.1200/JCO.2003.09.140, 12885837.
14. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, et al. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2007, 5:998-1033.
15. Anderson H, Thatcher N, Walling J, Hansen H. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 1996, 74:460-462. 10.1038/bjc.1996.382, 2074628, 8695365.
16. Rajdev L, Goldberg G, Hopkins U, Sparano JA. A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma. Med Oncol 2006, 23:369-376. 10.1385/MO:23:3:369, 17018894.
17. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Annals of surgical oncology 2006, 13:1035-1046. 10.1245/ASO.2006.08.011, 16865597.
18. Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 2000, 89:303-313. 10.1002/1097-0142(20000715)89:2<303::AID-CNCR15>3.0.CO;2-1, 10918160.
19. Miyanishi K, Ishiwatari H, Hayashi T, Takahashi M, Kawano Y, Takada K, Ihara H, Okuda T, Takanashi K, Takanashi S, et al. A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization. Jpn J Clin Oncol 2008, 38:268-274. 10.1093/jjco/hyn015, 18375446.
20. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of hepatology 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke Van M, Oosterom van AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
22. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966. 10.1200/JCO.2006.07.9525, 17452677.
23. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:3778-3785. 10.1200/JCO.2008.20.9007, 2727286, 19581537.